Tag Archives: myelodysplastic syndrome

August, 2018

21 August
Lixte Biotechnology and Moffitt Cancer Center to Initiate Trial Evaluating LB-100 in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome

EAST SETAUKET, NY, Aug. 21, 2018 (GLOBE NEWSWIRE) — Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that it has entered into a Clinical Trial Agreement and Exclusive License Agreement with Moffitt Cancer Center to conduct a Phase 1b/2 study of the safety and therapeutic benefit of Lixte’s lead clinical compound, LB-100, in patients with …
Share

21 August
FDA Grants Orphan Drug Designation to Syros’ Investigational Treatment for Acute Myeloid Leukemia

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SY-1425 for the treatment of acute myeloid leukemia (AML). SY-1425, an oral first-in-class …
Share

10 February
Study Finds Genetic Profiling Can Guide Stem Cell Transplantation for Patients with Myelodysplastic Syndrome

A single blood test and basic information about a patient’s medical status can indicate which patients with myelodysplastic syndrome (MDS) are likely to benefit from a stem cell transplant, and the intensity of pre-transplant chemotherapy and/or radiation therapy that is likely to produce the best results, according to new research …
Share

8 August
MEI Pharma and Helsinn Partner to Develop AML Drug in a Potential $464 Million Deal

LUGANO, Switzerland and SAN DIEGO, Aug. 8, 2016 PRNewswire — Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that they have entered into an exclusive …
Share

23 March
MEI Pharma’s Lead Cancer Drug Fails in Phase II Study

MEI Pharma’s lead cancer drug failed to meet the primary goal in a mid-stage study, causing shares to drop to a 52-week low. The company announced top-line data from a Phase II clinical trial evaluating its investigational drug candidate Pracinostat in combination with azacitidine in patients with previously untreated intermediate-2 …
Share